AZ/MSD PARP inhibitor Lynparza fails in colorectal cancer
Lynparza was being tested by itself and alongside Avastin as a first-line maintenance treatment for colorectal cancer that has not progressed following first-line induction. At an interim analysis, an indpendent data monitoring panel found neither regimens could improve upon Avastin's combination with chemotherapy in terms of stalling tumor progression or death.
https://www.fiercepharma.com/pharma/merck-astrazeneca-pull-plug-phase-3-lynparza-trial-colorectal-cancer
[This event further opens the door for ONCY's pelareorep in combination with a PARP inhibitor - such as with Pfizer’s FDA-approved PARP inhibitor, Talzenna. Pfizer picked up the drug in its $14 billion acquisition of Medivation in 2017, when it was already way behind PARP players AstraZeneca, Tesaro and Clovis Oncology.]